News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
San Antonio biomed firm looks to raise $20 million
September 24, 2015

Daniel Lee, CEO of Aperion Biologics Inc., identifying new funding sources has been a challenge for bioscience companies.

By W. Scott Bailey, San Antonio Business Journal

Aperion Biologics Inc. is taking another step toward American commercialization of its flagship medical device. The San Antonio-based company, which is seeking to carve out its niche in a $2 billion human tissue products and technology market, has filed a Regulation A public offering and is seeking to raise $20 million through a sale of common stock.

Aperion is a commercial-stage company focused on expanded opportunities in the regenerative medicine arena - an area where San Antonio is gaining significant attention nationally and internationally. It has developed and patented a technique to make animal-tissues usable for human applications without causing rejection.
Aperion has received a CE Mark, giving it regulatory approval to market and distribute its Z-Lig product in Europe.

"This additional financing will enable us to execute our commercialization plans for the European Union and other international markets," Aperion Biologics CEO Daniel Lee told me.

The company has also secured FDA unconditional approval to conduct a pivotal clinical trial in the U.S. for the Z-Lig.

Regulation A, an exemption from registration for smaller issuers of securities under SEC rules, was recently updated and expanded by the SEC, as mandated by the federal Jumpstart Our Business Startups (JOBS) Act. The new rules, referred to as Regulation A+, are designed to facilitate smaller companies' access to capital and provide investors with more investment choices.

The number of Aperion shares that will be offered, as well as the price range per share, have not yet been determined, according to company officials. The offering will be conducted by WR Hambrecht + Co., the sole underwriter.

Aperion has gained some significant exposure. In December, the company had an opportunity to pitch potential investors during the World Stem Cell Summit's inaugural RegMed Capital Conference, which was held in San Antonio and attended by industry leaders from across the globe. Yet access to capital remains a hurdle.

"It has been challenging to identify funding for medtech companies in San Antonio and elsewhere around the country," Lee said. "The Regulation A+ opportunity came at the right time for Aperion and we are fortunate to work with WR Hambrecht, who was at the forefront of making this legislation a reality."

 

Stay informed. Subscribe to BioMed SA news alerts.